| Autor: |
El-Saka MH; Department of Physiology, Tanta University, Tanta, Egypt., Abo El Gheit RE; Department of Physiology, Tanta University, Tanta, Egypt., El Saadany A; Department of Pharmacology, Tanta University, Tanta, Egypt., Alghazaly GM; Department of Internal Medicine, Tanta University, Tanta, Egypt., Marea KE; Department of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt., Madi NM; Department of Physiology, Tanta University, Tanta, Egypt. |
| Jazyk: |
angličtina |
| Zdroj: |
Archives of physiology and biochemistry [Arch Physiol Biochem] 2023 Dec; Vol. 129 (4), pp. 933-942. Date of Electronic Publication: 2021 Feb 25. |
| DOI: |
10.1080/13813455.2021.1887265 |
| Abstrakt: |
This study declared effect of spexin (SPX) on renal dysfunction in obese rats and its potential mitigating mechanisms which could mediated via galanin receptor-2 (GALR-2). Thirty two 32 Wistar male rats were arranged into four groups: control, high fat/fructose diet (HFFD), HFFD + SPX and HFFD + M871 (galanin receptor 2 antagonist)+SPX. At the termination of the experiment, urine volume, body mass index, Lee index and mean arterial blood pressure were assessed. Renal function was evaluated. Lipid profile, fasting glucose, insulin, insulin resistance and SPX levels were estimated. Also, renal histopathological, immunohistochemical and relative gene expression of renal tissue were done. Also, renal protein carbonyl, reduced glutathione, interferon gamma, monocyte chemoattractant protein-1, interleukin-10 and hydroxyproline were determined.Our results explored that SPX treatment prominently mitigated the metabolic changes and renal dysfunction induced by HFFD via GALR-2. SPX improved insulin resistance, dyslipidemia, renal oxidative stress, inflammation, apoptosis, and fibrosis. So, SPX can be considered as prospective therapeutic agent for treating renal dysfunction. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
